

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

Claim 16. (currently amended): A method for monitoring the clinical effectiveness of the administration of a formulation comprising one or more therapeutic growth factor proteins in the treatment of coronary artery disease, the method comprising the steps of :

- a. selecting a patient displaying symptoms of coronary artery disease;
- b. administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein selected from the group consisting of FGF-1, FGF-2, ~~VEGF~~PIGF, and mixtures thereof by inhalation therapy;
- c. obtaining a sample of a biological fluid from the patient displaying symptoms of coronary artery disease;
- d. performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
- e. determining, based on monitoring the amount of CPK-MB present in the fluid, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
- f. depending on the results of the step e), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, ~~VEGF~~PIGF, and mixtures thereof; and
- g. repeating steps c) through f) until the assayed levels of CPK-MB in the biological fluid indicates the clinical effectiveness of the administration of the pharmaceutical formulation and amelioration of the symptoms of coronary

artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 17. (canceled)

Claim 18. (canceled)

Claim 19. (canceled)

Claim 20. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a dry powder formulation.

Claim 21. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a liquid aerosol formulation.

Claim 22. (previously presented): The method of claim 16, wherein the symptoms of coronary artery disease are brought on by a condition selected from the group consisting of myocardial infarct, unstable angina, an acute anginal attack and reperfusion injury.

Claim 23. (previously presented): The method of claim 22, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

Claim 24. (currently amended): A method for monitoring the clinical effectiveness of the administration of a potentially therapeutic pharmaceutical formulation selected from the group consisting of FGF-1, FGF-2, ~~VEGF~~PIGF, and mixtures thereof, in the treatment of chronic coronary artery disease, the method comprising the steps of:

- a. selecting a patient displaying symptoms of chronic coronary artery disease;
- b. administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein selected from the group consisting of FGF-1, FGF-2, ~~VEGF~~PIGF, and mixtures thereof by inhalation therapy;

- c. obtaining a sample of a biological fluid from the patient displaying symptoms of chronic coronary artery disease;
- d. performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
- e. determining, based on monitoring the amount of CPK-MB present in the fluid, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
- f. depending on the results of the step e), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, ~~VEGF~~PIGF, and mixtures thereof; and
- g. repeating steps c) through f) until the assayed levels of CPK-MB in the biological fluid indicates the clinical effectiveness of the administration of the pharmaceutical formulation and amelioration of the symptoms of chronic coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 25. (canceled)

Claim 26. (canceled)

Claim 27. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a dry powder formulation.

Claim 28. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a liquid aerosol formulation.

Claims 29-35. (canceled)